Art. 37 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…

In forcecited 2×

Where an application for a marketing authorisation is submitted in respect of a medicinal product designated as an orphan medicinal product pursuant to Regulation (EC) No 141/2000 and that application includes the results of all studies conducted in compliance with an agreed paediatric investigation plan, and the statement referred to in Article 28(3) of this Regulation is subsequently included in the marketing authorisation granted, the ten-year period referred to in Article 8(1) of Regulation (EC) No 141/2000 shall be extended to twelve years.

The first paragraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned.

  • Opinion of Advocate General Emiliou delivered on 11 July 2024. Mylan IRE Healthcare Ltd v European Commission.Decision

    When the Commission granted an MA to Tobi Podhaler in 2011, [Implementing Decision C(2011) 5394 final granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘Tobi Podhaler – …

    11 Jul 2024 · 62022CC0237

  • Order of the General Court (Eighth Chamber), 3 September 2014. Shire Pharmaceutical Contracts Ltd v European Commission.Decision

    … letter of 18 October 2013, concerning whether the medicinal product Xagrid was eligible for the reward provided for in Article 37 of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on …

    3 Sep 2014 · 62013TO0583